Actively Recruiting
Randomized Study to Assess SHR-2173 Injection Added to Standard Care for Generalized Myasthenia Gravis
Led by Guangdong Hengrui Pharmaceutical Co., Ltd · Updated on 2026-10-22
60
Participants Needed
2
Research Sites
13 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are conducting a multicenter, randomized, double-blind, placebo-controlled Phase II clinical trial to evaluate SHR-2173 as an add-on therapy to standard care for people with generalized myasthenia gravis gMG. The study aims to assess the drugs efficacy, safety, pharmacokinetics, and pharmacodynamics compared to placebo. Participants have confirmed gMG and meet specific antibody and symptom criteria. Participants are assigned to one of three groups high-dose SHR-2173 injection, low-dose SHR-2173 injection, or placebo, all added to their standard care. The trial includes a 4-week screening period, followed by 24 weeks of treatment, and a 12-week safety follow-up. The study evaluates the impact of SHR-2173 on muscle strength and daily living activities related to gMG. During the study, participants will have regular assessments of their myasthenia gravis symptoms using scores like MG-ADL, QMG, and MGC, as well as quality of life and fatigue questionnaires. Safety monitoring includes tracking adverse events. The total participation lasts approximately 40 weeks, allowing researchers to understand SHR-2173s effects and safety profile in this patient population.
CONDITIONS
Brief Title
A Phase II Study of SHR-2173 Injection in Patients With Myasthenia Gravis
Research Team
K
Kunming Li
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here